{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:03:42Z","timestamp":1790053422363,"version":"4.0.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the cost-effectiveness of aumolertinib versus osimertinib as first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system, and to explore economic outcomes across clinically relevant subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model with three health states was developed over a 10-year horizon with a 28-day\u202fcycle length. Clinical inputs were derived from indirect evidence based on the AENEAS and FLAURA trials. In the base-case analysis, the progression-free survival (PFS) effect was informed by a published simulated treatment comparison, whereas the overall survival (OS) hazard ratio for aumolertinib versus osimertinib was conservatively set at 1.00. Costs and health outcomes were discounted at 5% annually. Outcomes included total costs, quality-adjusted life-years (QALYs), and incremental net monetary benefit (iNMB) at a willingness-to-pay threshold of 298,995 Chinese Yuan (CNY) per QALY. One-way sensitivity, probabilistic sensitivity, scenario, threshold, and exploratory subgroup analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the overall population, osimertinib was associated with a total cost of 193,447.40 CNY and 1.981 QALYs, whereas aumolertinib was associated with a total cost of 207,484.66 CNY and 2.000 QALYs. Compared with osimertinib, aumolertinib yielded an additional 0.019 QALYs at an additional cost of 14,037.26 CNY, resulting in an iNMB of \u22128,307.60 CNY. Thus, aumolertinib was not economically favorable in the base-case analysis. At the prespecified threshold, the probability of being cost-effective was 0.58 for osimertinib and 0.42 for aumolertinib. Scenario and threshold analyses showed that the results were sensitive to drug price and the comparative OS effect. Exploratory subgroup analyses showed differences in the direction of point estimates across subgroups, but uncertainty remained substantial across all subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Under the current Chinese pricing environment and available indirect comparative evidence, aumolertinib and osimertinib showed broadly similar economic profiles as first-line treatment for advanced EGFR-mutated NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1858476","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:28Z","timestamp":1790050948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of first-line aumolertinib versus osimertinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer in China"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuhua","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaolian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]},{"name":"Research Center for Clinical Pharmacy, Zhejiang University","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Pharmacy, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets west: ethnic differences in epidemiology and clinical Behaviors of lung Cancer between east Asians and Caucasians","volume":"30","author":"Zhou","year":"2011","journal-title":"Chin J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung Cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"CD010383","DOI":"10.1002\/14651858.CD010383.pub3","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","volume":"3","author":"Greenhalgh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.Ccr-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, Egfr-mutated advanced Nsclc","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-022-01695-2","article-title":"Aumolertinib: a review in non-small cell lung cancer","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/jco.21.02641","article-title":"Aeneas: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non\u2013small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/cam4.3733","article-title":"Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung Cancer patients","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"920479","DOI":"10.3389\/fphar.2022.920479","article-title":"Cost-effectiveness of Osimertinib versus standard Egfr-Tki as first-line treatment for Egfr-mutated advanced non-small-cell lung Cancer in China","volume":"13","author":"Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/14737167.2025.2518135","article-title":"Cost-utility analysis of Osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung Cancer with Egfr mutation","volume":"25","author":"Su","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1080\/14796694.2024.2395803","article-title":"Cost-effectiveness of Aumolertinib as first-line treatment for Egfr-mutated advanced nonsmall-cell lung Cancer","volume":"20","author":"Zhang","year":"2024","journal-title":"Future Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.clinthera.2018.12.007","article-title":"Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China","volume":"41","author":"Cai","year":"2019","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"key":"ref19","volume-title":"China Guidelines for Pharmacoeconomic Evaluations","year":"2020"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S1012","DOI":"10.1016\/j.annonc.2022.07.1131","article-title":"1005p indirect treatment comparisons of relative efficacy for Aumolertinib vs Osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"ref21","volume-title":"Health Technology Assessment Report: Pulmivex Film-Coated Tablets 55 Mg Center for Drug Evaluation","year":"2026"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e70393","DOI":"10.1002\/mco2.70393","article-title":"First-line third-generation EGFR tyrosine kinase inhibitor monotherapy for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis","volume":"6","author":"Du","year":"2025","journal-title":"MedComm"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.21037\/jtd-2026-1-0317","article-title":"First-line third-generation Egfr-Tkis for advanced Egfr-mutated non-small cell lung Cancer: a systematic review and network meta-analysis of randomized controlled trials","volume":"18","author":"Liu","year":"2026","journal-title":"J Thorac Dis"},{"key":"ref24","volume-title":"Assessment Report: Pulmivex Film-Coated Tablets 55 Mg (Aumolertinib Mesilate)","year":"2026"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator Egfr Tki as first-line treatment for Egfr-mutated advanced Nsclc: Flaura China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/ijc.30691","article-title":"Comparison of gefitinib, erlotinib and afatinib in non-small cell lung Cancer: a meta-analysis","volume":"140","author":"Yang","year":"2017","journal-title":"Int J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"Ipdfromkm: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non\u2013small cell lung cancer: an international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-022-01161-7","article-title":"Prices and clinical benefit of National Price-Negotiated Anticancer Medicines in China","volume":"40","author":"Zhang","year":"2022","journal-title":"PharmacoEconomics"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"469580231170729","DOI":"10.1177\/00469580231170729","article-title":"Promoting access to innovative anticancer medicines: a review of drug Price and National Reimbursement Negotiation in China","volume":"60","author":"Mingge","year":"2023","journal-title":"Inquiry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e107161","DOI":"10.1371\/journal.pone.0107161","article-title":"Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858r mutation after first-line Egfr-Tkis for advanced non-small cell lung Cancer: a meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","article-title":"Comparison of clinical outcomes of patients with non-small-cell lung Cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis","volume":"72","author":"Sheng","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","article-title":"Osimertinib versus standard of care Egfr Tki as first-line treatment in patients with Egfrm advanced Nsclc: Flaura Asian subset","volume":"14","author":"Cho","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"740091","DOI":"10.3389\/fonc.2021.740091","article-title":"First-line treatments for extensive-stage small-cell lung Cancer with immune checkpoint inhibitors plus chemotherapy: a network meta-analysis and cost-effectiveness analysis","volume":"11","author":"Kang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1858476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:29Z","timestamp":1790050949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1858476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":36,"alternative-id":["10.3389\/fpubh.2026.1858476"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1858476","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1858476"}}